Sorrento Therpt (SRNE)
$8.21
0.18 (2.15%)
SRNE Stock Quote Delayed 30 Minutes
7 Meme Stocks That You Shouldn’t Touch With a 10-Foot Pole
Not all meme stocks are "bad." But with retail investors beginning to realize the heavy lift that awaits them, you should avoid these seven.
Louis Navellier's Top 6 Stocks for 2021
He found Apple at $1.49… Intel at $3.60... Amazon at $46. Now, investing legend Louis Navellier is revealing his Top 6 Stocks for 2021 — FREE!
Download His Free Report Here:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
-
Market Cap
2.35B
PE Ratio
-8.64
EPS
-0.95
Volume (Avg. Vol.)
2.74M
Day's Range
8.16 - 8.49
52-Week Range
5.17 - 19.39
Dividend & Yield
N/A (N/A)
SRNE Stock Predictions, Articles, and Sorrento Therpt News
SRNE Stock: The Big News Lifting Sorrento Therapeutics Today
Today, SRNE stock is on the move in a big way as investors price in two key announcements made by the company regarding clinical trials.
The Dip Is an Opportunity in Sorrento Therapeutics Stock
The pullback in SRNE stock has cleared 40%. Sorrento has too many ways to win for the stock to stay down forever.
Sorrento Therapeutics Is Betting On A Longer Play, So Should You
The delay of Sorrento Therapeutics’ Covid-19 vaccine has weakened SRNE stock, but the company has plenty more in the pipeline.
Sorrento Stock Is Little More Than a Day Trade Now
Nearly a third of SRNE stock's float has been sold short. This sets up a catalyst for a short-term move, but avoid a long-term investment.
Government and Institutional Support Are Positives for Sorrento Stock
Sorrento just received a grant of up to $34 million from Washington, while multiple institutions own meaningful amounts of SRNE stock.
SRNE Stock: California Testing Approval Stokes Sorrento Therapeutics
Sorrento Therapeutics is poised to roll out clinical testing trials in California. SRNE stock is up in pre-market trading on Wednesday as the country continues to post record Covid-19 diagnoses and hospitalizations.
Sorrento Therapeutics Remains a Buy Between $6 and $6.50
Sorrento Therapeutics has seen SRNE stock close between $5.76 and $8.20 in the past month. Here’s why it’s time for investors to be careful.
Covid-19 Vaccine Makers Still Make Sense, Including Sorrento Therapeutics
SRNE stock fell out of favor as bigger vaccine developers grabbed the headlines but that may change soon.
Don’t Chase the Rebound in Sorrento — It’s Not Worth the Risk
SRNE stock may be bouncing back, but given its grab bag of issues, skip out on this fading coronavirus play.
The Shock and Awe of Sorrento Therapeutics Is Long Gone
Sorrento Therapeutics was an early pandemic winner. But as the world closes in on multiple vaccines, SRNE stock looks to be too late.
Hopefuls Back Sorrento Therapeutics But Time Is a Factor
Investors seeking a longshot coronavirus play continue to eye SRNE stock despite Sorrento Therapeutics' high risk and continued volatility.
Sorrento Stock Doesn’t Offer Any Upside as Vaccine Frontrunners Emerge
The Covid-19 race is close to ending. It seems unlikely that Sorrento stock can pull a rabbit out of a hat with the frontrunners emerging.
Windows of Opportunity Are Tightening for Sorrento Therapeutics
Thanks to Sorrento Therapeutics’ all-out pivot to address the Covid-19 pandemic, SRNE stock initially became one of the most popular investments. But as both the vaccine and treatment race tighten, the risks multiply.
Don’t Bail on Sorrento Therapeutics Stock Just Yet
SRNE stock has tumbled as larger players have shown progress toward a vaccine. But this isn't just a vaccine play, and the story is far from over.
Avoid Sorrento Therapeutics, Which Is Still Burning Cash With No End In Sight
Avoid Sorrento Therapeutics which is still burning cash with no end in sight. SRNE stock will become more diluted as the company consistently raises cash.
Sorrento Therapeutics Hoping Better Late Than Never Works in Vaccine Competition
In this competition, Sorrento is a different beast because it's not just working on a vaccine, it's working on Covid-19 testing, neutralizing antibodies and preventive “shields,” among other products. That's a relevant, robust pipeline, but it hasn't been enough to prevent SRNE stock from sliding 61% from its 52-week high.
